≥99% HPLCBatch testedIdentity by MS, purity by HPLC
Lot numberedCertificate filed per lot
Cold stored2 to 8 °C until dispatch
CJC-1295 with DAC
2mg lyophilised powderCAS 446262-90-4
A GHRH 1-29 analogue carrying a drug-affinity-complex modification for longer persistence, used in GHRH receptor and growth-hormone axis studies.
£20.90per vial, VAT included
In stock, dispatched same day before 16:00
- Free shipping on UK orders over £20.00
- Same day dispatch on orders placed before 16:00
- Batch certificate in the COA Database
Sold for research purposes only. For in-vitro laboratory research. Not a medicine and not for human or animal consumption. Supplied to qualified individuals aged 18 and over; you confirm this at checkout.
Research overview
CJC-1295 with DAC is a synthetic analogue of growth-hormone-releasing hormone, built on a modified GRF 1-29 backbone with an added C-terminal lysine that carries a drug affinity complex. It is studied in vitro and in preclinical models of GHRH receptor signalling and growth-hormone axis regulation. Supplied at 2mg for in-vitro laboratory research only.
The GHRH receptor is a G protein-coupled receptor on pituitary somatotroph cells, and its activation raises intracellular cAMP. Native GHRH is broken down quickly by peptidases. The D-alanine at position 2 of this sequence is intended to resist that cleavage. The drug affinity complex is a maleimide-based group that has been described as binding serum albumin covalently, which is reported to extend how long the peptide persists in albumin-containing systems.
In the laboratory, GHRH analogues are used in receptor-binding assays, cAMP accumulation assays and primary pituitary cell cultures, where growth-hormone release into the medium is measured by immunoassay. Stability work often follows peptide persistence in serum-containing media by HPLC or mass spectrometry. This product is supplied as a lyophilised powder.
Research areas
- GHRH receptor binding and cAMP signalling
- Growth-hormone release in pituitary cell cultures
- Albumin binding and peptide persistence in media
- Peptide stability and degradation profiling
- Structure-activity studies of GRF 1-29 analogues
Specifications
- CAS number
- 446262-90-4
- Molecular formula
- C165H269N47O46
- Molecular weight
- 3647.2
- Sequence
- Y-[D-Ala]-DAIFTQSYRKVLAQLSARKLLQDILSR-K(DAC)-NH2 (Mod GRF 1-29 backbone + C-terminal Lys with DAC / maleimidopropionyl; D-Ala at position 2; amide)
- Form
- lyophilised powder
- Purity
- ≥99% (HPLC)
- Also known as
- CJC-1295-DAC, DAC:GRF
- Supplied as
- 2mg per vial, lyophilised powder
Storage and handling
Store the lyophilised powder in a freezer, away from moisture and light, and let the vial reach room temperature before opening. Reconstitute with an appropriate laboratory diluent, aliquot, and avoid repeated freeze and thaw.
Certificates of analysis
Each lot of CJC-1295 with DAC is released with a certificate recording identity and purity. Enter the lot number printed on your vial on the lab testing page to view it.
Questions
How does CJC-1295 with DAC differ from CJC-1295 without DAC?
Both share a modified GRF 1-29 backbone. The with-DAC form adds a C-terminal lysine carrying a maleimide-based drug affinity complex, reported to bind albumin and lengthen persistence. The without-DAC form has no such group.
How is it supplied and stored?
It is supplied as a lyophilised powder in a 2mg vial. Keep it cold, dry and protected from light, then reconstitute with a suitable laboratory diluent when it is needed.
Is CJC-1295 with DAC a medicine?
No. It is supplied strictly for in-vitro laboratory research. It is not a medicine, food or supplement, and it is not for human or animal use. Buyers must be aged 18 or over.
